Cantor Colburn, one of the largest full-service IP law firms in the U.S., is the fastest also the growing patent firm over the last ten years. Cantor Colburn is ranked #4 for design patents, #6 for utility patents and #10 for trademarks. The firm’s Litigation Department has also received national recognition. More than 100 attorneys and agents provide counsel to clients worldwide from offices in Hartford, Washington, D.C., Atlanta, Houston, and Detroit. Cantor Colburn is proud to be named one of the Top 100 Firms for Minority Attorneys (IP Law360).
Our Pharmaceutical IP Services Practice Group handles litigation, patent prosecution, inter partes reviews and other Patent Office review proceedings, opinions, landscapes, competitive intelligence, transactional services, portfolio management, biosimilar and interchangeable biological drugs, and more. The Pharmaceutical IP Services Practice Group operates as a team, in which each practice area – patent and litigation – excels at its distinct area, while providing a seamless, one-stop service experience for clients seeking comprehensive pharmaceutical IP services.
With highly specialized knowledge and in-depth understanding of clients' businesses, the firm supports the technological innovations that are driving the world economy.
Green Griffith focuses exclusively on IP issues involving pharmaceuticals, chemistry and biotechnology—specializing in litigation. Our attorneys share decades of litigation experience assisting both generics and brand companies navigate the Hatch-Waxman Act. As stated in AIM Patent 1000 (2017): “Green, Griffith is a uniquely talented and experienced intellectual property firm that has been making serious waves in the biopharmaceutical market. As for the Green, Griffith modus operandi, they are tirelessly committed to helping their clients succeed; collaborating with their clients as strategic partners – albeit partners who happen to be excellent at litigation.”
Acknowledged leaders in our field, we partner with our clients to provide strategic formulation development and litigation counseling concerning IP and FDA exclusivity issues affecting 505(b)(1), 505(b)(2) and ANDA applications. Pre-litigation, we provide strategies and opinions on API and excipient selection, trade dress, formulation attributes and labeling. Our trial attorneys—who have hard science backgrounds in chemistry, biology and/or biotechnology—then work with each client to execute the desired strategy—whether this involves litigation in the federal courts or IPR practice before the PTAB.
HGF is a leading European intellectual property law firm engaged by companies and research organisations having patents, brands and designs at the core of their business. We provide commercially-relevant, cost-effective advice for IP matters.
HGF advises on the creation of strategic IP assets around the world. HGF provides world-class expertise in the origination, enforcement and defence of IP rights. Our approach is proactive and we work with our clients to find cost-effective, practical solutions to commercial issues.HGF provides:
As a team of chemists and biochemists with many years of experience, Hamm&Wittkopp represents its clients in all areas of intellectual property. One of our strengths lies in the fields of chemistry and pharmaceutics – focusing on generic pharmaceuticals and biosimilars. We offer high-level services, from analysing and clarifying the IP situation, e.g. by oppositions and nullity actions against troublesome patents, to securing your innovations via patent applications and defending your interests in litigations. Our structure allows us to provide tailor-made support in all IP matters, whereby we act with flexibility and efficiency – adapting to the needs of each individual case.
Now celebrating its 50th year, Lerner David thrives on what has become unique in the legal world: an IP boutique dealing with all aspects of intellectual property. Our firm devotes itself exclusively to IP. Our philosophy of “clients for life” is not a slogan, but rather a demonstrable achievement of which we are most proud.
“When we need someone to really dig in and fight a good fight, we typically turn to Lerner David.” This comment, from a Fortune 100 client, reflects our attention to detail and our focus on achieving, in as efficient a manner as possible, our clients’ business goals. When the stakes are high—as they typically are in ANDA cases—you can count on Lerner David to understand your business, legal, and regulatory needs.
Our Hatch-Waxman practice, involving both ANDAs and 505(b)(2)s, is varied and complex. Our team includes skilled courtroom advocates and crafty IP strategists, and we bring to bear our backgrounds and advanced degrees in chemistry, biochemistry, biology, biotechnology, chemical engineering, materials science, genetics, and bacteriology, among others. We help clients plan for every stage of a HatchWaxman challenge—from Orange Book strategy and FLBs through litigation, tactical use of post-grant proceedings, and appeal. Since its passage in 1984, Lerner David has represented some of the world’s most recognized pharma companies in hundreds of ANDA cases brought under the Hatch-Waxman Act.